How many employees does Bridge Biotherapeutics, Inc. have?

Bridge Biotherapeutics, Inc. has 24 employees.

What industry does Bridge Biotherapeutics, Inc. belong to?

Bridge Biotherapeutics, Inc. is in the industry of: Research.

What are Bridge Biotherapeutics, Inc.'s official social media profiles?

Bridge Biotherapeutics, Inc. Linkedin Page Bridge Biotherapeutics, Inc. Facebook Page Bridge Biotherapeutics, Inc. Twitter Page

What tech stack does Bridge Biotherapeutics, Inc. use?

Some of the popular technologies that Bridge Biotherapeutics, Inc. uses are: Sitecore, MySQL, Magento.

What are Bridge Biotherapeutics, Inc.'s office addresses?

Bridge Biotherapeutics, Inc. has 3 known office addresses: 58, Pangyo-ro 255 Beon-gil, Bundang-gu, Suite 303, KR One Broadway, 14th Floor, Cambridge, MA, 02142, US 58, Pangyo-ro 255 Beon-gil, Bundang-gu, Suite 303, Seongnam-si, Gyeung-gi Do 13486, Kr.

What is Bridge Biotherapeutics, Inc.'s estimated annual revenue?

Bridge Biotherapeutics, Inc.'s revenue is $6,300,000

What is Bridge Biotherapeutics, Inc.'s open headcount?

Bridge Biotherapeutics, Inc. has no job postings yet.

What is the number of ad campaigns for Bridge Biotherapeutics, Inc.?

Bridge Biotherapeutics, Inc. has no advertisements yet.

What is the number of recent news articles about Bridge Biotherapeutics, Inc.?

Bridge Biotherapeutics, Inc. has 3 news articles.

Bridge Biotherapeutics, Inc. - Pubrio Company Profile & Intent

Bridge Biotherapeutics, Inc.

South Korea · Research

Research

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs such as ulcerative colitis, fibrotic diseases, and cancers. The company is developing BBT-401, a first-in-class Pellino-1 inhibitor for the treatment of ulcerative colitis, BBT-877, a novel autotaxin inhibitor for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF), and BBT-176, a potent targeted cancer therapy for non-small cell lung cancer (NSCLC) with C797S triple EGFR mutations.